The Iceland-based generic pharmaceuticals company, Actavis, announced last week that it has entered into a binding letter of intent with QRxPharma to launch MoxDuo® IR in the United States. The product launch in the U.S. is expected in the third quarter of 2012. Claudio Albrecht, CEO of Actavis said, “This partnership ... Read More...
Actavis group
Actavis Group and Japan’s ASKA Pharmaceutical formally signed contracts recently establishing a new joint company called Actavis ASKA K.K. The new business will be headquartered in Tokyo. The joint company intends to enter the Japanese generic pharmaceutical market right away in April 2009. ASKA will hold a 55 percent stake in ... Read More...